Tech • IA • Crypto
50 articles analyzed by AI / 149 total
OpenEvidence is seeking $200 million in funding at a $20 billion valuation as of July 20, 2026, reflecting rapid growth in AI healthcare solutions. This significant capital raise highlights strong investor confidence in the expanding AI health tech sector.
A leading global hospital is conducting AI tests aimed at revolutionizing healthcare delivery, showcasing practical clinical adoption of AI technology as of July 2026. This step marks a significant advancement in integrating AI into routine medical practice.
Frederick Health Hospital is applying artificial intelligence to improve medical treatment for patients susceptible to seizures as of July 2026, aiming to enhance patient outcomes and quality of care through AI-driven medical approaches.
UVA Health developed guiding principles for AI use in healthcare by July 2026, establishing ethical and practical standards to guide future AI adoption. These standards aim to ensure responsible and effective AI integration in medicine.
Timmins and District Hospital partnered with Unity Health Toronto to deploy an AI tool predicting the need for neurosurgery as of July 2026, enhancing preoperative planning and patient care. This collaboration represents a step forward in AI-supported surgical decision-making.
In a collaboration announced in 2023, Johns Hopkins and the FDA developed a tool to detect hidden bias in medical AI training data, aiming to enhance AI accuracy and fairness. This innovation addresses a critical challenge in trustworthy AI healthcare applications.
Tempus announced plans to acquire Personalis in 2026 to integrate Molecular Residual Disease detection into its AI-enabled precision oncology platform. This $1.5 billion deal aims to advance AI-driven personalized cancer diagnostics and treatment.
ALZAI Health Corp secured an exclusive global license for AI-based liver disease risk identification technology as of July 2026. This development expands the application of AI diagnostics in liver disease worldwide.
A new AI scan analyzing chest muscle has been demonstrated to predict heart failure and mortality risk, offering improved early diagnosis as of July 2026. Clinical studies validate AI's potential to assess cardiovascular risk more accurately.
Heartflow launched an AI-powered staging tool for coronary plaque assessment in 2026, promising enhanced accuracy in diagnosing and planning treatment for heart disease. This tool is expected to improve clinical outcomes in cardiovascular care.